Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases

Lancet

Volumn 347, Issue 9002, 1996, Pages 649-653

  Pantel, Klaus ^a   Izbicki, Jakob ^c   Passlick, Bernward ^b   Angstwurm, Matthias ^a   Häussinger, Karl ^d   Thetter, Olaf ^d   Riethmüller, Gert ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; TUMOR CELL;

EID: 0029867674     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91203-9     Document Type: Article

References (28)

1. Minna JD, Pass H, Glatstein E, et al. Cancer of the lung. In: de Vita VTJ, Hellmann S, Rosenberg SA, eds. Cancer: principles & practice of oncology. Philadelphia: Lippincott, 1989: 591-705.
2. Lindemann F, Schlimok G, Dirschedl P, Witte J, Reithmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992; 340: 685-89.
3. Schlimok G, Funke I, Holzmann B, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 8672-76.
4. Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993; 53: 1027-31.
5. Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165-73.
6. Debus E, Weber K, Osborn M. Monoclonal cytokeratin antibodies that distinguish simple from stratified squamous epithelia. EMBO J 1982; 1: 1641-47.
7. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP-complexes). J Histochem Cytochem 1984; 32: 219-29.
8. Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small cell lung cancer. J Clin Oncol 1994; 12: 1827-32.
9. Momburg F, Moldenhauer G, Hämmerling GJ, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987; 47: 2883-91.
10. Latza U, Niedobitek G, Schwarting R. Ber-EP4: new monoclonal antibody which distinguishes epithelial from mesothelia. J Clin Pathol 1990; 43: 213-19.
11. Harrison WJ. The total cellularity of the bone marrow in man. J Clin Path 1962; 15: 254-59.
12. Page A, Nakhle G, Mercier C, et al. Surgical treatment of bronchogenic carcinoma: the importance of staging in evaluating late survival. Can J Surg 1987; 30: 96-99.
13. Grunow N, Goertchen R. Mikrometastasen der Wirbelsäule in einem unselektierten Obduktionsgut bei fast 100%iger Obduktionsfrequenz (Görlitzer Studie). Pathologe 1991; 12: 270-74.
14. Burkhardt R, Frisch B, Kettner G. The clinical study of micrometastatic cancer by bone biopsy. Bull Cancer 1980; 67: 291-305.
15. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-24.
16. Pantel K, Schlimok G, Kutter D, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51: 4712-15.
17. Pantel K, Dickmanns A, Zippelius A, et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995; 87: 1162-68.
18. Bos IL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-89.
19. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318-27.
20. Hayashi N, Ito I, Yanagisawa A, et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995; 345: 1257-59.
21. Datta YH, Adams PT, Drobyski WR. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-82.
22. Wood DP, Banks ER, Humphries S, McRoberts JW, Rangnekar M, Lexington KY. Identification of micrometastases in patients with prostate cancer. J Urol 1994; 151: 303.
23. Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. Am J Pathol 1993; 142: 1111-18.
24. Krismann M, Todt B, Schröder J, et al. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769-75.
25. Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981; 32: 23-27.
26. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
27. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83.
28. Göttlinger HG, Funke I, Johnson JP, Gokel JM, Rietmüller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986; 38: 47-53.